Abstract
In order to improve the poor results of treatment of childhood acute myeloblastic leukemia (AML), we applied the Berlin-Frankfurt-Münster (BFM) strategy for patients with AML admitted to the clinic of our institute. The reference group included 29 patients treated with courses “7+3” and “5+2” (conventional doses of cytosine arabinoside, ara-C, and daunorubicin). The results of this treatment were as follows: remission was achieved in 58.6% of patients relapse-free survival at 42 months was 21.4%. Between February 1990 and May 1994, a total of 46 consecutive patients with AML were treated according to the BFM strategy (complication from AML-BFM-83 and AML-BFM-87 studies); there were 17 males and 29 females. Mean age was 8 years (range 1-15 years). The French-American-British (FAB) subtype distribution was as follows: MO-4.25%, Ml-6.45%, M2-19.1% M3-10.65%, M4-23.4%, M5-27.75%, M6-6.4%. All patients received an 8-day induction course: conventional doses of ara-C, daunorubicin 30 mg/m2 daily-six doses, and etoposide 150 mg/m2 a day–three doses. A sixdrug (prednisolone; 6-mercapto-purine, 6-MP; vincristine; ara-C, cyclophosphamide; doxorubicin) consolidation course lasted 6 weeks. Twenty three patients received intensification therapy: 20 patients with high doses of ara-C plus etoposide and three patients with high-dose ara-C plus mitoxantrone. Twelve patients did not receive an intensification course. CNS prophylaxis included ara-C intrathecally and cranial gamma-irradiation (18 Gy). As a result of the treatment 35 patients (76%) achieved complete remission (CR). There were 11 induction failures: the toxic deaths (13%) and five primary refractory disease (10%). One patient died in CR after the intensification course. Of 34 patients completing the intensive phase of therapy, five patients relapsed (15%). The actuaial event-free survival is 63% at 51 months.
In conclusion our cohort of AML patients is characterized by a peculiar distribution of FAB subtypes with a prevalence of M4 and M5 subtypes needing intensive regimens of therapy. The BFM strategy of intensive treatment showed high efficacy in the presented group of patients with AML.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
J. Bennett, D. Catovsky, M.T. Daniel et al. Proposed revised criteria for the classification of acute myeloid leukemia. Ann Int Med, 1985, 103: 626–629
Bennett JM, Catovsky D, Daniel MT et al. Criteria for diagnosis of acute leukemia of megakaryocyte lineage (M7): a report of French-American British Cooperative Group Ann Intern Med 1985, 103: 460
U. Creutzig, J. Ritter and G. Shellong. Identification of two risk groups in childhood acute myelogenous leukemia after therapy intensification in study AML-BFM-83 as compared with study AML-BFM-78. Blood, vol.75 N10(May 15), 1990, 1932–1940
Cretzig U, Ritter J, Zimmermann and Shellong G. Does cranial irradiation reduce the risk of bone marrow relapse in acute myelogeneous leukemia? Unexpected results of the childhood acute myeloid leukemia study BFM-87. J Clin Oncol 1993, vol 11, N 2, 279–286
Preisler H, Davis RB, Krishner J et al. Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: a cancer and Leukemia Group B study. Blood, 1987, 69, 1441.
R.J. Wells, W.G. Woods, I.D. Buckley et al. Treatment of newly diagnosed children and adolescents with acute myeloid leukemia: Childrens Cancer Group study. J. Clin Oncol Vol 12, N 11(November), 1994; 2367–2377.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1997 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Maschan, A.A. et al. (1997). Results of Intensive Chemotherapy of Acute Myeloblastic Leukemia in Children According to the Berlin-Frankfurt-Münster Strategy: A Single-Institution Trial. In: Büchner, T., Schellong, G., Ritter, J., Creutzig, U., Hiddemann, W., Wörmann, B. (eds) Acute Leukemias VI. Haematology and Blood Transfusion / Hämatologie und Bluttransfusion, vol 38. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-60377-8_113
Download citation
DOI: https://doi.org/10.1007/978-3-642-60377-8_113
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-64379-8
Online ISBN: 978-3-642-60377-8
eBook Packages: Springer Book Archive